Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'

Lung Cancer. 2020 Oct:148:179-180. doi: 10.1016/j.lungcan.2020.06.001. Epub 2020 Jun 5.

Authors

Yuji Inagaki¹, Akihiro Tamiya²

Affiliations

¹ Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan. Electronic address: inagaki.yuji.vr@mail.hosp.go.jp.
² Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan. Electronic address: tamiya.akihiro.tz@mail.hosp.go.jp.

PMID: 32586660
DOI: 10.1016/j.lungcan.2020.06.001

No abstract available

Publication types

Letter
Comment

MeSH terms

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Exons / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation

Substances

Acrylamides
Aniline Compounds
osimertinib
EGFR protein, human
ErbB Receptors